BACKGROUND: Administering 2 separate vaccines for seasonal and pandemic influenza was necessary in 2009. Therefore, we conducted a randomized trial of monovalent 2009 H1N1 influenza vaccine (2009 H1N1 vaccine) and seasonal trivalent inactivated influenza vaccine (TIV; split virion) given sequentially or concurrently in previously vaccinated children. METHODS: Children randomized to 4 study groups and stratified by age received 1 dose of seasonal TIV and 2 doses of 2009 H1N1 vaccine in 1 of 4 combinations. Injections were given at 21-day intervals and serum samples for hemagglutination inhibition antibody responses were obtained prior to and 21 days after each vaccination. Reactogenicity and adverse events were monitored. RESULTS: All combinations of vaccines were safe in the 531 children enrolled. Generally, 1 dose of 2009 H1N1 vaccine and 1 dose of TIV, regardless of sequence or concurrency of administration, was immunogenic in children ≥ 10 years of age; children <10 years of age required 2 doses of 2009 H1N1 vaccine. CONCLUSIONS: Vaccines were generally well tolerated. The immune responses to 2009 H1N1 vaccine were adequate regardless of the sequence of vaccination in all age groups but the sequence affected titers to TIV antigens. Two doses of 2009 H1N1 vaccine were required to achieve a protective immune response in children <10 years of age. CLINICAL TRIALS REGISTRATION: NCT00943202.
RCT Entities:
BACKGROUND: Administering 2 separate vaccines for seasonal and pandemic influenza was necessary in 2009. Therefore, we conducted a randomized trial of monovalent 2009 H1N1 influenza vaccine (2009 H1N1 vaccine) and seasonal trivalent inactivated influenza vaccine (TIV; split virion) given sequentially or concurrently in previously vaccinated children. METHODS:Children randomized to 4 study groups and stratified by age received 1 dose of seasonal TIV and 2 doses of 2009 H1N1 vaccine in 1 of 4 combinations. Injections were given at 21-day intervals and serum samples for hemagglutination inhibition antibody responses were obtained prior to and 21 days after each vaccination. Reactogenicity and adverse events were monitored. RESULTS: All combinations of vaccines were safe in the 531 children enrolled. Generally, 1 dose of 2009 H1N1 vaccine and 1 dose of TIV, regardless of sequence or concurrency of administration, was immunogenic in children ≥ 10 years of age; children <10 years of age required 2 doses of 2009 H1N1 vaccine. CONCLUSIONS: Vaccines were generally well tolerated. The immune responses to 2009 H1N1 vaccine were adequate regardless of the sequence of vaccination in all age groups but the sequence affected titers to TIV antigens. Two doses of 2009 H1N1 vaccine were required to achieve a protective immune response in children <10 years of age. CLINICAL TRIALS REGISTRATION: NCT00943202.
Authors: Kawsar R Talaat; Michael E Greenberg; Michael H Lai; Gunter F Hartel; Christine H Wichems; Steven Rockman; Robert J Jeanfreau; M Rita Ghosh; Martin L Kabongo; Charmaine Gittleson; Ruth A Karron Journal: J Infect Dis Date: 2010-11-01 Impact factor: 5.226
Authors: Terry Nolan; Jodie McVernon; Maryanne Skeljo; Peter Richmond; Ushma Wadia; Stephen Lambert; Michael Nissen; Helen Marshall; Robert Booy; Leon Heron; Gunter Hartel; Michael Lai; Russell Basser; Charmaine Gittleson; Michael Greenberg Journal: JAMA Date: 2009-12-21 Impact factor: 56.272
Authors: Tristan W Clark; Manish Pareek; Katja Hoschler; Helen Dillon; Karl G Nicholson; Nicola Groth; Iain Stephenson Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Raburn M Mallory; Elissa Malkin; Christopher S Ambrose; Terramika Bellamy; Li Shi; Tingting Yi; Taff Jones; George Kemble; Filip Dubovsky Journal: PLoS One Date: 2010-10-29 Impact factor: 3.240
Authors: Huiying Chua; Susan S Chiu; Eunice L Y Chan; Shuo Feng; Mike Y W Kwan; Joshua S C Wong; J S Malik Peiris; Benjamin J Cowling Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Sharon E Frey; David I Bernstein; Rebecca C Brady; Wendy A Keitel; Hana El Sahly; Nadine Georges Rouphael; Mark J Mulligan; Robert L Atmar; Srilatha Edupuganti; Shital M Patel; Michelle Dickey; Irene Graham; Edwin L Anderson; Diana L Noah; Heather Hill; Mark Wolff; Robert B Belshe Journal: Vaccine Date: 2014-11-11 Impact factor: 3.641
Authors: Sinthujan Jegaskanda; Thakshila H Amarasena; Karen L Laurie; Hyon-Xhi Tan; Jeff Butler; Matthew S Parsons; Sheilajen Alcantara; Janka Petravic; Miles P Davenport; Aeron C Hurt; Patrick C Reading; Stephen J Kent Journal: J Virol Date: 2013-10-09 Impact factor: 5.103
Authors: Karen L Kotloff; Natasha B Halasa; Christopher J Harrison; Janet A Englund; Emmanuel B Walter; James C King; C Buddy Creech; Sara A Healy; Rowena J Dolor; Ina Stephens; Kathryn M Edwards; Diana L Noah; Heather Hill; Mark Wolff Journal: Pediatr Infect Dis J Date: 2014-08 Impact factor: 2.129